Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 334 Carcinoma, Non-Small-Cell Lung 262 Ovarian Neoplasms 177 Lung Neoplasms 129 Neoplasms 92 Fallopian Tube Neoplasms 77 Carcinoma, Ovarian Epithelial 63 Neoplasm Metastasis 59 Esophageal Neoplasms 58 Stomach Neoplasms 49 Head and Neck Neoplasms 45 Squamous Cell Carcinoma of Head and Neck 44 Triple Negative Breast Neoplasms 40 Endometrial Neoplasms 37 Adenocarcinoma of Lung 32 Urinary Bladder Neoplasms 28 Esophageal Squamous Cell Carcinoma 26 Unspecified Adult Solid Tumor, Protocol Specific 24 Uterine Cervical Neoplasms 23 Carcinoma 23 Melanoma 22 Breast Neoplasms, Male 22 Small Cell Lung Carcinoma 20 Prostatic Neoplasms 20 Parkinson Disease 4, Autosomal Dominant Lewy Body 20 Adenocarcinoma Of Esophagus 20 Recurrence 19 Brenner Tumor 18 Adenocarcinoma, Bronchiolo-Alveolar 18 Peritoneal Neoplasms 16

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Malignant Disease × Paclitaxel × Clear all

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡